Takeda Pharmaceutical Co (4502) Price & Analysis

Compare

7 Followers

4502 Stock Chart & Stats

¥4222.00

-¥15.00(-0.36%)

At close: Jan 08 4:00 PM EST

¥4222.00

-¥15.00(-0.36%)

Day’s Range― - ―

52-Week Range¥3,916.00 - ¥5,328.00

Previous CloseN/A

Volume3.70M

Average Volume (3M)4.35M

Market Cap

¥8.31T

Enterprise Value¥12.48T

Total Cash (Recent Filing)¥761.94B

Total Debt (Recent Filing)¥4.85T

Price to Earnings (P/E)72.6

Beta0.44

Next Earnings

May 13, 2026

EPS Estimate

10.42

Next Dividend Ex-DateN/A

Dividend Yield4.11%

Share Statistics

EPS (TTM)65.74

Shares Outstanding1,590,987,800

10 Day Avg. Volume4,483,280

30 Day Avg. Volume4,345,693

Financial Highlights & Ratios

PEG Ratio-2.51

Price to Book (P/B)1.00

Price to Sales (P/S)1.52

P/FCF Ratio9.15

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥5,450.00

Price Target Upside29.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessFavorable Phase III results for orexin receptor agonist oveporexton for NT1 presented, showing significant improvement across NT1 symptoms.

Market PerformanceEntyvio continues to grow faster than the market, withstanding biosimilar step edits and branded competition.

Product DevelopmentSmooth progress on the late-stage development product is positive, with no serious treatment-related adverse events reported.

Bears Say

Government Pricing InitiativesEntyvio faces potential pricing headwinds via two government initiatives: MFN and IRA.

Pricing PressureMFN poses a threat not just because of its direct implications, but also because of the way in which prices are determined for 340b.

Takeda Pharmaceutical Co News

Takeda raises FY25 core EPS view to 486 yen from 479 yen

Raises FY25 revenue view to 4.53B yen from 4.5B yen. The company said, “Takeda (TAK) has updated its...

3d ago

TAK

Takeda reports Q3 core EPS 428 yen vs. 443 yen last year

Reports Q3 revenue 3.41B yen vs. 3.53B yen last year. Takeda (TAK) chief financial officer, Milano Furuta, commented:...

3d ago

TAK

Takeda announces U.S. availability of Gammagard Liquid ERC

Takeda (TAK) announced the U.S. availability of Gammagard Liquid ERC with less than or equal to two microgram/mL...

10d ago

TAK

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: T-REX 2X INVERSE MSTR...

16d ago

ENB

Takeda resumed with an Overweight at Morgan Stanley

Morgan Stanley analyst Shinichiro Muraoka resumed coverage of Takeda (TAK) with an Overweight rating and 6,200 yen price...

19d ago

TAK

Leerink views ‘major deal’ on Entyvio as positive for Halozyme

Leerink notes Halozyme (HALO) issued a press release announcing that it entered into an exclusive license agreement with...

24d ago

TAK

HALO

Halozyme announces global collaboration, license agreement with Takeda

Halozyme Therapeutics (HALO) announced the company entered into a global collaboration and exclusive license agreement with Takeda (TAK)...

24d ago

TAK

HALO

Alumis price target raised to $32 from $18 at Guggenheim

Guggenheim analyst Yatin Suneja raised the firm’s price target on Alumis (ALMS) to $32 from $18 and keeps...

25d ago

TAK

ALMS

Takeda, Protagonist Therapeutics submit rusfertide new drug application to FDA

Takeda (TAK) and Protagonist Therapeutics (PTGX) announced the submission of a new drug application to the FDA seeking...

27d ago

TAK

PTGX

Takeda Posts Lower Nine-Month Revenue but Higher Profit, Lifts Dividend and Trims Growth Outlook

Takeda Pharmaceutical Co ( ($JP:4502) ) has shared an update. Takeda reported a 3.3% year-on-year decline in revenue...

4d ago

TKPHF Upcoming Earnings Report: What to Expect?

Takeda Pharmaceutical Co (TKPHF) is scheduled to report 3rd quarter earnings on 01/29/2026, before the market opens. Regarding...

5d ago

H.C. Wainwright remains bullish on Xoma following creative Takeda deal

H.C. Wainwright says Xoma (XOMA) took “a nice ride down the creativity road again with nice pipeline expansion,”...

1M ago

TAK

XOMA

Takeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Psoriasis Results

Takeda Pharmaceutical Co ( ($JP:4502) ) just unveiled an update. Takeda reported positive topline results from two pivotal...

2M ago

Takeda and Protagonist Showcase Promising Rusfertide Results at ASH 2025

Takeda Pharmaceutical Co ( ($JP:4502) ) has provided an announcement. Takeda and Protagonist Therapeutics presented new 52-week data...

2M ago

4502 FAQ

What was Takeda Pharmaceutical Co Ltd’s price range in the past 12 months?

Takeda Pharmaceutical Co Ltd lowest stock price was ¥3916.00 and its highest was ¥5328.00 in the past 12 months.

What is Takeda Pharmaceutical Co Ltd’s market cap?

Takeda Pharmaceutical Co Ltd’s market cap is ¥8.31T.

When is Takeda Pharmaceutical Co Ltd’s upcoming earnings report date?

Takeda Pharmaceutical Co Ltd’s upcoming earnings report date is May 13, 2026 which is in 101 days.

How were Takeda Pharmaceutical Co Ltd’s earnings last quarter?

Takeda Pharmaceutical Co Ltd released its earnings results on Jan 28, 2026. The company reported ¥65.74 earnings per share for the quarter, beating the consensus estimate of ¥43.14 by ¥22.6.

Is Takeda Pharmaceutical Co Ltd overvalued?

According to Wall Street analysts Takeda Pharmaceutical Co Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Takeda Pharmaceutical Co Ltd pay dividends?

Takeda Pharmaceutical Co Ltd pays a Semiannually dividend of ¥100 which represents an annual dividend yield of 4.11%. See more information on Takeda Pharmaceutical Co Ltd dividends here

What is Takeda Pharmaceutical Co Ltd’s EPS estimate?

Takeda Pharmaceutical Co Ltd’s EPS estimate is 10.42.

How many shares outstanding does Takeda Pharmaceutical Co Ltd have?

Takeda Pharmaceutical Co Ltd has 1,590,987,800 shares outstanding.

What happened to Takeda Pharmaceutical Co Ltd’s price movement after its last earnings report?

Takeda Pharmaceutical Co Ltd reported an EPS of ¥65.74 in its last earnings report, beating expectations of ¥43.14. Following the earnings report the stock price went down -0.936%.

Which hedge fund is a major shareholder of Takeda Pharmaceutical Co Ltd?

Currently, no hedge funds are holding shares in JP:4502

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited, headquartered in Tokyo, Japan, is a global biopharmaceutical leader focused on the research, development, manufacturing, and marketing of innovative medicines. The company operates in several therapeutic areas, including oncology, gastroenterology, neuroscience, rare diseases, and vaccines. Takeda's core products include treatments for various cancers, gastrointestinal disorders, and rare diseases, alongside a growing portfolio of vaccines and biologics.

Takeda Pharmaceutical Co (4502) Earnings & Revenues

Historic Earnings Reports

4502 Company Deck

4502 Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflected a mixed financial performance with strong cash flow and pipeline advancements but was overshadowed by significant challenges such as the VYVANSE generic impact, ENTYVIO's slower growth, and foreign exchange headwinds. The partnership with Innovent Biologics provides a positive outlook for the oncology pipeline, but current financial pressures remain a concern.View all JP:4502 earnings summaries

4502 Stock 12 Month Forecast

Average Price Target

¥5,450.00

▲(29.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3938":"¥3,938","6201":"¥6,201","4503.75":"¥4,503.8","5069.5":"¥5,069.5","5635.25":"¥5,635.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥6K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5450,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥5.45K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥4.70K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3938,4503.75,5069.5,5635.25,6201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4835,4940,5045,5150,5255,5360,5465,5570,5675,5780,5885,5990,6095,{"y":6200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4835,4882.307692307692,4929.615384615385,4976.923076923077,5024.2307692307695,5071.538461538462,5118.846153846154,5166.153846153846,5213.461538461538,5260.7692307692305,5308.076923076923,5355.384615384615,5402.692307692308,{"y":5450,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4835,4824.615384615385,4814.2307692307695,4803.846153846154,4793.461538461538,4783.076923076923,4772.692307692308,4762.307692307692,4751.923076923077,4741.538461538462,4731.153846153846,4720.7692307692305,4710.384615384615,{"y":4700,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3939.774,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3999.076,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4025.857,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4145.419,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4407.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4273.487,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4179.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4294.991,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4121.979,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4368.301,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4260,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4153,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4835,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 67, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >